Results 191 to 200 of about 892,099 (304)

Immune-Related Cystitis Following Immune Checkpoint Inhibitor Therapy: A Report of Two Cases. [PDF]

Case Rep Med
Zhao C, Ge Y, Zhang X.
europepmc   +1 more source

Rewiring Pyroptosis to Potentiate Cancer Immunotherapy via a Gasdermin D Agonist Bypassing Caspase‐3

Advanced Science, EarlyView.
This work introduces a small‐molecule agonist, DIBDO, that bypasses Casp‐3 to directly trigger GSDMD‐mediated pyroptosis in tumors. Activated by glutathione, DIBDO generates singlet oxygen and molecular iodine, blocking Casp‐3 pathways and inducing immunogenic cell death.
Dan Zhao, Lingling Zhang, Yue Wen, Lianghui Cheng, Sidan Tian, Fanling Meng, Liang Luo   +6 more
wiley   +1 more source

Immune checkpoint inhibitor-related pancreatitis with fulminant type 1 diabetes mellitus: a case report. [PDF]

Front Immunol
Niu L, Sun S, Zhang L, Song Y, Huang Q, Sun J.   +5 more
europepmc   +1 more source

SOX5 Orchestrates Malignant Evolution via Promoter‐Centric Chromatin Remodeling in MYC‐Driven B‐Cell Lymphoma

Advanced Science, EarlyView.
In MYC‐enforced B‐cell lymphoma, SOX5 occupies promoter‐proximal regulatory regions and is associated with reduced chromatin accessibility at the PCNP locus. PCNP repression promotes proliferative remodeling by limiting apoptosis and cell‐cycle restraint.
Yiyou Mao, Zhenyuan Jia, Xiao‐Qin Mu, Ruilin Wang, Jianli Ma, Qingyuan Zhang, Yuwei Deng   +6 more
wiley   +1 more source

Immune checkpoint inhibitor treatment - real-world use and outcomes in Sweden 2015-2023. [PDF]

Ups J Med Sci
Illergard K, Soto P, Arpegård J, Schiza A, Pahnke S.   +4 more
europepmc   +1 more source

Identifying a Csmd3+ Microglial Subpopulation that Drives Cold‐to‐Hot Transition and Immune‐Cure in Glioblastoma

Advanced Science, EarlyView.
The study establishes an immune‐cure (ICu) mouse model based on a TMEMed G422TN‐GBM system that faithfully recapitulates human TMEMed GBM. scRNA‐seq analysis reveals a Csmd3+ microglial subset with innate immune memory (IIM) potential that potently suppresses GBM growth, drives a TME cold‐to‐hot transition, and induces 100% ICu in long‐term survival ...
Hai‐Feng Jiang, Pan‐Pan Gao, Yu‐Wen Du, Li‐Qin Wu, En‐Zhi Yin, Qi An, Ze‐Hua Ding, Jin‐Wen Shi, Ya Shu, Ruoqiao Chen, Feng Liu, Mingfeng Li, Xiao Qian Chen   +12 more
wiley   +1 more source

Clinical and Biochemical Recovery From Immune Checkpoint Inhibitor-Induced Diabetes With Seroconversion of GAD Antibodies. [PDF]

Diabetes Care
Chen LR, Cooksley T, Kochhar R, Titus Raj EJ, Lorigan P, Adam S.   +5 more
europepmc   +1 more source

A 1-year follow-up study on checkpoint inhibitor-induced colitis : results from a European consortium

: Background: Data regarding the clinical outcome of patients with immune checkpoint inhibitor (ICI)-induced colitis are scant. We aimed to describe the 12-month clinical outcome of patients with ICI-induced colitis.
Kav, T., Corazza, G.R., Biagi, F., Kotsakis, A., Muscarella, S., Porcari, S., Santacroce, G., Savarino, E.V., Cammarota, G., Pugliese, D., Spagnuolo, R., Ellul, P., Bertani, L., Natalello, G., Barberio, B., Corallo, S., Locati, L.D., Vanoli, A., Scalvini, D., Dal Buono, A., Premoli, A., De Lisi, G., Gambini, G., Delliponti, M., Caprioli, F., Klersy, C., Eder, P., Foteinogiannopoulou, K., Agustoni, F., Schiepatti, A., Silvestris, N., Chiellino, S., Vecchi, M., Vernero, M., Groechenig, H.P., Koutroubakis, I., Demarzo, M.G., Armuzzi, A., Festa, S., Contaldo, A., Sottotetti, F., Lenti, M.V., Cuce, M., Lasagna, A., Musella, V., Pedrazzoli, P., Gabbiadini, R., De Ruvo, M., Alimenti, E., Ribaldone, D.G., Ianiro, G., Mengoli, C., Buda, A., Blesl, A., Broglio, G., Argyriou, K., Rossi, C.M., Pagani, A., Cannizzaro, R., Jauregui, Aranzazu, Cappello, M., Di Sabatino, A., Lepore, F., Aronico, N., Gasbarrini, A., Franzoi, M., Morano, D., Merli, S., de Andreis, F. Borrelli   +68 more
core  

Programmable Encapsulation Enables On‐Demand Proliferation of Therapeutic Bacteria for Potent Cancer Immunotherapy

Advanced Science, EarlyView.
A programmable encapsulation technology is developed to reduce bacterial immunogenicity and proliferation after systemic administration. The cross‐linked polymer networks around individual bacteria enable immunogenic shielding and permit selective proliferation in tumors, allowing the bacteria to convert tumor‐accumulated ammonia into L‐arginine and ...
Jianhui Yang, Ao Peng, Shuaiqiang Li, Yaning Huang, Jian Yan, Leyuan Wang, Zhihui Zhu, Fei‐Long Liu, Erbao Bian, Yang Liu, Dasheng Tian, Fenghe Li, Qi Liu   +12 more
wiley   +1 more source

When urine sparkles: tumor lysis syndrome after immune checkpoint inhibitor therapy. [PDF]

J Bras Nefrol
Ramos AR, Duarte R, Alves RV.
europepmc   +1 more source